Cargando…

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic data suggest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurata, Keiji, James-Bott, Anna, Tye, Mark A., Yamamoto, Leona, Samur, Mehmet K., Tai, Yu-Tzu, Dunford, James, Johansson, Catrine, Senbabaoglu, Filiz, Philpott, Martin, Palmer, Charlotte, Ramasamy, Karthik, Gooding, Sarah, Smilova, Mihaela, Gaeta, Giorgia, Guo, Manman, Christianson, John C., Payne, N. Connor, Singh, Kritika, Karagoz, Kubra, Stokes, Matthew E., Ortiz, Maria, Hagner, Patrick, Thakurta, Anjan, Cribbs, Adam, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth C., Oppermann, Udo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834298/ https://www.ncbi.nlm.nih.gov/pubmed/36631435 http://dx.doi.org/10.1038/s41408-023-00787-w

Ejemplares similares

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance
por: Tye, Mark A., et al.
Publicado: (2022)

Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq
por: Philpott, Martin, et al.
Publicado: (2021)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2017)

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
por: Keller, Tracy L., et al.
Publicado: (2012)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Selective Inhibitors of a Human Prolyl Hydroxylase (OGFOD1) Involved in Ribosomal Decoding
por: Thinnes, Cyrille C., et al.
Publicado: (2019)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Kinetic Landscape of a Peptide Bond-Forming Prolyl Oligopeptidase
por: Czekster, Clarissa M., et al.
Publicado: (2017)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

Structure and Mechanism of a Viral Collagen Prolyl Hydroxylase
por: Longbotham, James E., et al.
Publicado: (2015)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
por: Waumans, Yannick, et al.
Publicado: (2015)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Induced-fit Mechanism for Prolyl Endopeptidase
por: Li, Min, et al.
Publicado: (2010)

The role of prolyl oligopeptidase, understanding the puzzle
por: García-Horsman, J. Arturo
Publicado: (2020)

Phosphate–Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1
por: Shen, Zhong-Jian, et al.
Publicado: (2016)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
por: Cribbs, Adam P., et al.
Publicado: (2021)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Prolyl endopeptidase-like is a (thio)esterase involved in mitochondrial respiratory chain function
por: Rosier, Karen, et al.
Publicado: (2021)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
por: Holt-Martyn, James P., et al.
Publicado: (2019)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Editorial: Peptidyl-Prolyl Isomerases in Human Pathologies
por: Tuccinardi, Tiziano, et al.
Publicado: (2019)

Role of prolyl hydroxylation in the molecular interactions of collagens
por: Rappu, Pekka, et al.
Publicado: (2019)

Distribution of Peptidyl-Prolyl Isomerase (PPIase) in the Archaea
por: Anchal,, et al.
Publicado: (2021)

Regulation of AU-Rich Element RNA Binding Proteins by Phosphorylation and the Prolyl Isomerase Pin1
por: Shen, Zhong-Jian, et al.
Publicado: (2015)

Targeting Prolyl Endopeptidase with Valproic Acid as a Potential Modulator of Neutrophilic Inflammation
por: Abdul Roda, Mojtaba, et al.
Publicado: (2014)

Prolyl Isomerization-Mediated Conformational Changes Define ATR Subcellular Compartment-Specific Functions
por: Biswas, Himadri, et al.
Publicado: (2022)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ro0jpog6ucooch414v01cuk7ds